Screener
Myriad Genetics MYGN Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Myriad Genetics’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 6:05 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000899923-26-000038
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Common stock, 94.4 and 93.5 shares outstanding at March 31, 2026 and December 31, 2025, respectively | 0.9 | 0.9 |
| Additional paid-in capital | 1,492.6 | 1,489.0 |
| Accumulated other comprehensive income | 0.7 | 0.8 |
| Accumulated deficit | (1,156.8) | (1,122.7) |
| Total stockholders' equity | 337.4 | 368.0 |
| Total liabilities and stockholders’ equity | $673.7 | $706.6 |
Item 1. Financial Statements.
FAQ
- What is Myriad Genetics's total equity?
- Myriad Genetics (MYGN) reported total equity of $337.4M in Q1 2026.
- How has Myriad Genetics's total equity changed year-over-year?
- Myriad Genetics's total equity decreased by 52.1% year-over-year, from $704.9M to $337.4M.
- What is the long-term trend for Myriad Genetics's total equity?
- Over 5 years (2020 to 2025), Myriad Genetics's total equity has grown at a -16.0% compound annual growth rate (CAGR), from $881M to $368M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Myriad Genetics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude